SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, M. PEŠEK, P. ZATLOUKAL, V. KOLEK, F. SALAJKA, L. KOUBKOVÁ, H. ČOUPKOVÁ and M. ZEMANOVÁ. The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts). In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.075.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)
Authors SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution), M. PEŠEK (203 Czech Republic), P. ZATLOUKAL (203 Czech Republic), V. KOLEK (203 Czech Republic), F. SALAJKA (203 Czech Republic), L. KOUBKOVÁ (203 Czech Republic), H. ČOUPKOVÁ (203 Czech Republic) and M. ZEMANOVÁ (203 Czech Republic).
Edition 13th Central European Lung Cancer Conference, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.392
RIV identification code RIV/00216224:14110/12:00060611
Organization unit Faculty of Medicine
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.075
UT WoS 000305842300076
Keywords in English lung cancer; erlotinib
Changed by Changed by: prof. MUDr. Jana Skřičková, CSc., učo 1808. Changed: 14. 2. 2013 21:46.
Abstract
This analysis, The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients, presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.
PrintDisplayed: 23. 5. 2022 05:08